Pharmala Biotech Holdings, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Pharmala Biotech Holdings, Inc.

Æterna Zentaris, Inc.

Medicure, Inc.

Crescita Therapeutics, Inc.

Valeo Pharma, Inc.

Telescope Innovations Corp.

Revive Therapeutics Ltd.

PreveCeutical Medical, Inc.

Core One Labs, Inc.

PharmaTher Holdings Ltd.

XORTX Therapeutics, Inc.

Why is Pharmala Biotech Holdings, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Pharmala Biotech Holdings, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Pharmala Biotech Holdings, Inc.

0.0%

0.11

116.34%

S&P/TSX 60

28.13%

1.43

14.72%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

13.58%

EBIT Growth (5y)

14.26%

EBIT to Interest (avg)

-2.04

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.49

Sales to Capital Employed (avg)

0.44

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.82

EV to EBIT

-8.79

EV to EBITDA

-9.49

EV to Capital Employed

8.88

EV to Sales

14.14

PEG Ratio

Dividend Yield

ROCE (Latest)

-101.00%

ROE (Latest)

-72.66%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

25What is working for the Company

NET SALES(HY)

At CAD 0.79 MM has Grown at 182.67%

ROCE(HY)

Highest at 0%

NET PROFIT(Q)

Highest at CAD 0 MM

RAW MATERIAL COST(Y)

Fallen by -88.64% (YoY

OPERATING PROFIT(Q)

Highest at CAD 0.03 MM

EPS(Q)

Highest at CAD 0

-5What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at CAD -0.97 MM

PRE-TAX PROFIT(Q)

At CAD -0.51 MM has Fallen at -27.66%

NET PROFIT(Q)

At CAD -0.5 MM has Fallen at -27.59%

Here's what is working for Pharmala Biotech Holdings, Inc.

Net Sales

At CAD 0.79 MM has Grown at 182.67%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (CAD MM)

Net Profit

Highest at CAD 0 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Net Profit

At CAD 0 MM has Grown at 100%

over average net sales of the previous four periods of CAD -0.39 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Operating Profit

Highest at CAD 0.03 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (CAD MM)

EPS

Highest at CAD 0

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CAD)

Raw Material Cost

Fallen by -88.64% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Pharmala Biotech Holdings, Inc.

Operating Cash Flow

Lowest at CAD -0.97 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CAD MM)

Pre-Tax Profit

At CAD -0.51 MM has Fallen at -27.66%

over average net sales of the previous four periods of CAD -0.4 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CAD MM)

Net Profit

At CAD -0.5 MM has Fallen at -27.59%

over average net sales of the previous four periods of CAD -0.39 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CAD MM)